Neuroinflammation plays a major role in brain excitability and may contribute to the development of epilepsy. Prostaglandin E2 (PGE2) is a direct mediator of inflammatory responses and, through EP receptors, plays an important role in neuronal excitability. Pharmacological evidence supports that centrally-administered EP1 and EP3 receptor antagonists reduced acutely evoked seizures in rats. Translation of these findings would benefit from evidence of efficacy with a more clinically relevant route of delivery and validation in another species. In the current study we investigated whether the systemic administration of EP1 and EP3 agonists and antagonists modulate pentylenetetrazole (PTZ)-induced seizures in mice. In addition, it was examined whether these compounds alter Na+, K+-ATPase activity, an enzyme responsible for the homeostatic ionic equilibrium and, consequently, for the resting membrane potential in neurons. While the systemic administration of EP1 and EP3 antagonists (ONO-8713 and ONO-AE3-240, respectively) attenuated, the respective agonists (ONO-DI-004 and ONO-AE-248) potentiated PTZ-induced seizures (all compounds injected at the dose of 10 µg/kg, s.c., 30 min before PTZ challenge). Co-administration of either EP1 or EP3 agonist with the respective antagonists nullified the anticonvulsant effects of EP1/3 receptor blockade. In addition, EP1 and EP3 agonists exacerbated PTZ-induced decrease of Na+, K+-ATPase activity in both cerebral cortex and hippocampus, whereas, EP1 and EP3 antagonists prevented PTZ-induced decrease of Na+, K+-ATPase activity in both structures. Our findings support and extend evidence that EP1 and EP3 receptors may be novel targets for the development of anticonvulsant drugs.
Keywords: EP1 receptor; EP3 receptor; Epilepsy; pentylenetetrazole; prostaglandin E2.
Conflict of interest statement
Characterization of EP receptor subtypes responsible for prostaglandin E2-induced pain responses by use of EP1 and EP3 receptor knockout mice.Br J Pharmacol. 2001 Jun;133(3):438-44. doi: 10.1038/sj.bjp.0704092. Br J Pharmacol. 2001. PMID: 11375261 Free PMC article.
Prostaglandin E receptor subtypes involved in stimulation of gastroduodenal bicarbonate secretion in rats and mice.J Physiol Pharmacol. 1999 Jun;50(2):155-67. J Physiol Pharmacol. 1999. PMID: 10424714
Modulation of pentylenetetrazol-induced seizures by prostaglandin E2 receptors.Neuroscience. 2008 Apr 9;152(4):1110-8. doi: 10.1016/j.neuroscience.2008.01.005. Epub 2008 Jan 12. Neuroscience. 2008. PMID: 18329178
Vasoconstriction induced by activation of EP1 and EP3 receptors in human lung: effects of ONO-AE-248, ONO-DI-004, ONO-8711 or ONO-8713.Prostaglandins Other Lipid Mediat. 2004 Oct;74(1-4):101-12. doi: 10.1016/j.prostaglandins.2004.07.003. Prostaglandins Other Lipid Mediat. 2004. PMID: 15560119
Possible cross-regulation of the E prostanoid receptors.Mol Carcinog. 2007 Aug;46(8):711-5. doi: 10.1002/mc.20347. Mol Carcinog. 2007. PMID: 17538953 Review.
Cited by 2 articles
G protein-coupled receptors in acquired epilepsy: Druggability and translatability.Prog Neurobiol. 2019 Dec;183:101682. doi: 10.1016/j.pneurobio.2019.101682. Epub 2019 Aug 24. Prog Neurobiol. 2019. PMID: 31454545 Review.
The COX-2/prostanoid signaling cascades in seizure disorders.Expert Opin Ther Targets. 2019 Jan;23(1):1-13. doi: 10.1080/14728222.2019.1554056. Epub 2018 Dec 2. Expert Opin Ther Targets. 2019. PMID: 30484341 Free PMC article. Review.